Zai Lab Limited
ZLAB US98887Q1040
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -52% | -52% | -11% | 0% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Chen Yajing CFO |
34.25 USD |
456 Sold |
15,617 USD |
01/10/2025 | 02/10/2025 |
| Smiley Joshua L O |
28.91 USD |
10,000 Bought |
289,100 USD |
10/09/2025 | 10/09/2025 |
| Smiley Joshua L O |
36.24 USD |
6,641 Sold |
240,643 USD |
15/08/2025 | 18/08/2025 |
| Edmondson Frazor Titus Iii CLO |
36.24 USD |
1,883 Sold |
68,232 USD |
15/08/2025 | 18/08/2025 |
| Chen Yajing CFO |
35.27 USD |
610 Sold |
21,513 USD |
14/08/2025 | 15/08/2025 |
| Chen Yajing CFO |
35.53 USD |
828 Sold |
29,419 USD |
14/08/2025 | 15/08/2025 |
| Du Ying CEO |
35.47 USD |
46,387 Sold |
1,645,287 USD |
12/08/2025 | 13/08/2025 |
| Du Ying CEO |
34.25 USD |
50,000 Sold |
1,712,555 USD |
12/08/2025 | 12/08/2025 |
| Du Ying CEO |
34.64 USD |
50,000 Sold |
1,731,815 USD |
08/08/2025 | 11/08/2025 |
| Du Ying CEO |
34.74 USD |
50,000 Sold |
1,737,155 USD |
08/08/2025 | 08/08/2025 |